ALDH1A3 Biomarker for Beta-Cell Dysfunction Detection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Type 2 diabetes fail to effectively address the progressive β-cell failure characterized by impaired insulin secretion and reduced β-cell mass, with existing therapies either preserving β-cell function or increasing metabolic demand, but not mechanistically linking these two components of β-cell dysfunction.

Innovation Solution

The discovery of ALDH1A3 as a biomarker for dysfunctional β-cells, allowing for the isolation and characterization of dedifferentiated β-cells, and the use of high-throughput screening methods to identify test agents that reduce ALDH1A3 expression, potentially reversing β-cell dysfunction by promoting insulin production and secretion.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing treatments preserve β-cell function by reducing metabolic demand, then β-cell function is maintained, but insulin secretion capability deteriorates progressively

Engineering Contradiction:

Improveβ-cell function preservationVSAvoidinsulin secretion capability

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent changes the metabolic parameter state of β-cells by inducing a shift from oxidative metabolism to glycolytic metabolism. This is achieved through pharmacological intervention that alters the metabolic phenotype, allowing β-cells to maintain function under different metabolic conditions and potentially reverse dedifferentiation while preserving insulin secretion capability

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces dynamic metabolic flexibility to β-cells, enabling them to switch between metabolic states. By inducing a metabolic shift, the treatment allows β-cells to adapt their metabolic profile dynamically, which may help maintain both function and insulin secretion capability under varying physiological conditions

Inventive Principle:

Principle #15Dynamics

2Productivity

If existing treatments increase β-cell performance and mass, then metabolic demand is met, but the mechanism linking impaired insulin secretion and reduced β-cell mass remains unclear

Engineering Contradiction:

Improveβ-cell performance and massVSAvoidmechanistic understanding of β-cell failure

Core Design Contradiction:

ProductivityVSLoss of information

Solution Approach 1:

The patent employs feedback mechanisms by using metabolic shift as a readout and intervention point. By monitoring metabolic state changes and using them to guide treatment, the approach provides a mechanistic link between metabolic phenotype and β-cell function, potentially revealing how metabolic alterations drive dedifferentiation and insulin secretion impairment

Inventive Principle:

Principle #23Feedback

Solution Approach 2:

The patent introduces metabolic shift as an intermediary mechanism that connects impaired insulin secretion and reduced β-cell mass. By identifying metabolic phenotype as a mediating factor, the treatment provides a mechanistic bridge between these two components of β-cell failure, allowing for targeted intervention at the metabolic level

Inventive Principle:

Principle #24Intermediary (Mediator)

3Difficulty of detecting and measuring

If β-cells undergo dedifferentiation, then β-cell dysfunction occurs, but the ability to identify and isolate dysfunctional β-cells is limited

Engineering Contradiction:

Improvedetection of dysfunctional β-cellsVSAvoidβ-cell dysfunction identification

Core Design Contradiction:

Difficulty of detecting and measuringVSReliability

Solution Approach 1:

The patent uses metabolic shift as a detectable marker for β-cell dysfunction. By associating specific metabolic phenotypes with dysfunctional states, the invention enables identification and isolation of dysfunctional β-cells through metabolic profiling, making the previously undetectable state observable and measurable

Inventive Principle:

Principle #32Color changes

Solution Approach 2:

The patent replaces traditional morphological or functional assays for identifying dysfunctional β-cells with metabolic profiling approaches. By substituting mechanical or biochemical detection methods with metabolic state analysis, the invention enables more sensitive and specific identification of dysfunctional β-cells based on their metabolic phenotype

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Data Source

PatentUS10732173B2Use of aldehyde dehydrogenase as biomarker for beta-cell dysfunction and loss

Publication Date: 2020.08.04 THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK

AI summary

Methods are provided for obtaining a sample of β cells from an isolated donor pancreas or isolated pancreatic islets and analyzing the sample using flow cytometry to determine the percentage of β cells in the sample that express detectable levels of ALDH1 A3. If the percentage of ALDH1 A3-expressing β cells in the sample is about 3% or lower, then it is possible to determine that the pancreas or islets are healthy enough for implantation into a subject, and implanting the pancreas or islets. If the percentage of ALDH1 A3-expressing cells is above about 5%, then it is determined that the pancreas or islets are not suitable for implantation into the subject and discarding the pancreas or islets. Isolated non-insulin-producing or low-insulin-producing pancreatic beta cells are also provided.